surmount-1 tirzepatide weight loss non-diabetic 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers SURMOUNT-1: Adults achieve weight loss

Book an appointment today for our Semaglutide treatment

Kumar P, Liu C, Hsu JW et al (2021) Glycine and N -acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial

Laboratory research record on GLP-1S [PMID: 39757501] PubMed laboratory record discussing GLP-1S in a research context

Consistency: The solution should flow freely when you tilt the vial

Trans fats impair insulin sensitivity and reduce GLP-1 secretion

Thyroid levels should be monitored